FINWIRES · TerminalLIVE
FINWIRES

BOM:543064

2 stories mentioning BOM:543064Updated 92d ago

Every FINWIRES story that references BOM:543064, newest first.

Research

Jefferies Downgrades Cohance Lifesciences to Underperform From Hold, Adjusts Price Target to INR300 From INR340

Cohance Lifesciences (NSE:COHANCE, BOM:543064) has an average rating of overweight and mean price target of 394.88 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

BOM:543064NSE:COHANCE
Asia

Cohance Lifesciences Names Chairman, Group CEO; Shares Surge 20%

Cohance Lifesciences (NSE:COHANCE, BOM:543064) appointed Umang Vohra as chairman and group CEO, effective May 1, according to a Monday filing to the Indian stock exchanges.He takes over from Vivek Sharma, who stepped down as executive chairman and director, and has been redesignated as the special advisor to the company, effective April 30.The company's shares jumped 20% in recent trade.

BOM:543064NSE:COHANCE

Track with the FINWIRES app suite

FolioX
FolioX
Track BOM:543064 in your portfolio
WheelAI
WheelAI
Analyze BOM:543064 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BOM:543064